ClinicalTrials.gg
TerminatedNCT04544995Updated Jan 21, 2026Results posted

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

A Phase 1 interventional study of Niraparib (Tablet for oral suspension) and Dostarlimab in Neoplasms, sponsored by GlaxoSmithKline. Terminated at 2 sites in United Kingdom. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
6 Months to 17 Years
Sex
All
01

Study summary

This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the paediatric population. This study will be conducted to determine the recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), safety, and efficacy of niraparib in combination with dostarlimab in paediatric participants with recurrent or refractory solid tumors.

02

Conditions studied

  • Neoplasms

Keywords

  • Dose escalation
  • Dose expansion
  • Dostarlimab
  • Niraparib
  • Osteosarcoma
  • Neuroblastoma
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 47 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part 1 and Part 2:

  • Participant is a child or an adolescent greater than or equal to (>=) 6 months to less than (\<) 18 years old at the time of /assent.
  • Participant with disease other than neuroblastoma has radiologically at screening that can be tracked as v1.1 target lesion(s).
  • Participant with neuroblastoma has measurable/evaluable target and/or non-target disease by INRC at screening. Neuroblastoma participants with recurrent/ bone that is metaiodobenzylguanidine (MIBG)-positive (or FDG-PET positive, for MIBG-nonavid tumors) as only site of disease are eligible.
  • Performance status must be >=60 percent on the scale for participants >16 years of age and >=60 percent on the Lansky scale for participants less than or equal to (\<=) 16 years of age.
  • Participant has adequate organ function.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of (WOCBP) or Is a WOCBP and using a method that is highly effective.
  • A male participant of is eligible to participate if he agrees to refrain from donating sperm plus, either be abstinent from heterosexual intercourse or must agree to use a male condom starting with the first dose of study treatment through at least 90 days after the last dose of study treatment.

For Part 1 only:

  • Participant has recurrent or refractory osteosarcoma, neuroblastoma, adrenocortical carcinoma, Ewing sarcoma, rhabdomyosarcoma, or any other solid tumor (excluding tumors of the central nervous system [CNS]) and must not be eligible for alternative curative treatment: i. Participants with non-CNS solid tumours other than osteosarcoma, neuroblastoma, adrenocortical carcinoma, Ewing sarcoma or rhabdomyosarcoma are required to have prior documented breast cancer susceptibility gene (BRCAness) mutational signature (mutational signature 3) on deoxyribonucleic acid (DNA) sequencing of tumor obtained in the relapsed/recurrent disease setting, within 6 (preferably 3) months of Cycle 1 Day 1.

ii. For participants with documented BRCAness mutational signature: Existing information on molecular profiling of the participant's tumor tissue must be through a molecular profiling platform such as Individualized Therapy for Relapsed in Childhood (INFORM). Molecular profile information must contain information from whole exome sequencing or whole genome sequencing, including the mutation status of BRCA1 and BRCA 2 and other homologous recombination DNA repair (HRR) pathway genes, mutational signatures including mutational signature 3, and tumor mutational burden (TMB).

iii. NOTE: Participants with recurrent or refractory osteosarcoma, neuroblastoma, adrenocortical carcinoma, Ewing sarcoma, or rhabdomyosarcoma are asked to provide documentation, if available, of the BRCAness mutational signature analysis on DNA sequencing of their tumour.

For Part 2A:

  • Participant has recurrent or refractory osteosarcoma and must not be eligible for alternative curative treatment.

Documentation of BRCAness mutational signature 3 will be requested, but not required, for enrollment.

  • Participant must confirm at screening that an archival or fresh tumor tissue sample is available for use, in retrospective exploratory biomarker analysis. Otherwise, enrolling site must discuss with Sponsor.

For Part 2B:

  • Participant has recurrent or refractory neuroblastoma and must not be eligible for alternative curative treatment. Documentation of BRCAness mutational signature 3 will be requested, but not required, for enrollment.
  • Participant must confirm at screening that an archival or fresh tumor tissue sample is available for use, in retrospective exploratory biomarker analysis. Otherwise, enrolling site must discuss with Sponsor.

Exclusion criteria

Exclusion Criteria:

For Part 1 and Part 2:

  • Participant has known to dostarlimab or niraparib, their components, or their .
  • Participant has a known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • Participant has active disease that has required systemic treatment in the past 2 years (that is [i.e.], with use of disease-modifying anti-rheumatic drugs, , or drugs). Replacement therapy (for example [e.g.], thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Participant has known active , carcinomatous meningitis, or both. Carcinomatous meningitis precludes a participant from study participation regardless of clinical stability.
  • Participant had a known additional (second primary) that progressed or required active treatment within the last 2 years.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection that requires systemic therapy.
  • Participant has a condition (such as transfusion-dependent anemia or thrombocytopenia), requirement for therapy, or laboratory abnormality that might confound the study results or interfere with the participant's participation for the full duration of the study treatment.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  • Participant has a known history of (HIV) (type 1 or 2 antibodies).
  • Participant has documented presence of HbsAg and/or at Screening or within 3 months prior to first dose of study intervention. Participants with a negative HbsAg and positive HbcAb result are eligible only if HBV DNA is negative.
  • Participant must not have a gastrointestinal condition, such as bowel obstruction, that can impact absorption of oral medications and is identified by clinical symptoms or CT scan, etc.
  • Participant has had any known Grade 3 or 4 anemia, neutropenia, and/or thrombocytopenia that was related to the most recent prior anti-cancer treatment and that persisted >4 weeks (28 days).
  • Participant has not recovered (i.e., to Grade ≤1 or to baseline) from prior systemic anticancer therapy-induced AEs. Note: Participants with alopecia, hearing impairment, Grade ≤2 neuropathy, Grade ≤2 fatigue, Grade ≤ 2 anaemia, and/or Grade ≤2 neutropenia are an exception to this criterion and may qualify for participation in the study.
  • Participant had toxicity related to prior immunotherapy that led to study treatment discontinuation.
  • Participant had treatment with systemic anticancer therapy ( agent or device, or approved chemotherapy, targeted therapy, immunotherapy, or other systemic therapy) within 3 weeks or 5 half-lives, whichever is shorter, prior to the first dose of study treatment, radiation therapy encompassing >20 percent of the bone marrow within 2 weeks prior to the first dose of study treatment, or any radiation therapy within 1 week prior to the first dose of study treatment.
  • Participant has not recovered adequately from AEs or complications from any major surgery prior to starting study treatment.
  • Participant has received a within 30 days of planned start of study treatment.
  • Participant has cardiovascular disease (e.g., significant cardiac conduction abnormalities, uncontrolled hypertension, cardiac arrhythmia or unstable angina, Grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, and history of cerebrovascular accident) within 6 months of enrolment.
  • Participant has heart rate- interval prolongation at screening >450 milliseconds (msec) or >480 msec for participants with bundle branch block.
  • Participant has received a solid organ transplant.
  • Participant has a documented presence of antibody at Screening or within 3 months prior to first dose of study intervention. NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled, if a confirmatory HCV RNA test is negative and the participant otherwise meets entry criteria.
  • Participant has a documented presence of HCV RNA at Screening or within 3 months prior to first dose of study intervention. NOTE: The HCV RNA test is optional and participants with negative HCV antibody test are not required to undergo HCV RNA testing as well.

For Part 2:

  • Participant has received prior therapy with an , anti-programmed cell death ligand 1, anti-programmed cell death-ligand 2, anti-cytotoxic T-lymphocyte-associated antigen-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways (with the exception of participants rolling over from Part 1 of the study: these participants are allowed to have received dostarlimab).
  • Participant has had prior treatment with a known poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor (with the exception of participants rolling over from Part 1 of the study: these participants are allowed to have received niraparib).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Part 1A: Dose Escalation

    Participants with body weight of ≥ 20 kilogram (kg) and who can swallow niraparib tablets will receive niraparib tablets and dostarlimab.

    Drug: Dostarlimab · Drug: Niraparib (Tablet)

  • Experimental
    Part 1B: Dose Escalation

    Participants who are \<8 years of age will receive niraparib TfOS and dostarlimab.

    Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab

  • Experimental
    Part 2 Safety Run-in

    Participants with osteosarcoma or neuroblastoma who are ≥8 years of age will receive niraparib TfOS and dostarlimab.

    Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab

  • Experimental
    Part 2A: Cohort Expansion for Osteosarcoma

    Participants with osteosarcoma will receive the RP2D of the combination of niraparib and dostarlimab.

    Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab · Drug: Niraparib (Tablet)

  • Experimental
    Part 2B: Cohort Expansion for Neuroblastoma

    Participants with neuroblastoma will receive the RP2D of the combination of niraparib and dostarlimab.

    Drug: Niraparib (Tablet for oral suspension) · Drug: Dostarlimab · Drug: Niraparib (Tablet)

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)

    DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.

    Time frame: Up to 42 days

  2. Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)

    DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.

    Time frame: Up to 42 days

  3. Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events

    Thrombocytopenia events were defined as treatment-related toxicities of Grade 3 or Grade 4 thrombocytopenia occurring within the first 42 days of study treatment. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0.

    Time frame: Up to 42 days

  4. Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

    PFS6 is defined as the percentage of participants without progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death at 6 months from the date of the first dose of study treatment. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

    Time frame: At Month 6

  5. Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)

    ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using International Neuroblastoma Response Criteria (INRC). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

    Time frame: Up to approximately 196 weeks

Secondary outcomes

  1. Part 1A and Part 1B: Objective Response Rate (ORR)

    ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR using RECIST v1.1 or INRC (for neuroblastoma participants only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

    Time frame: Up to approximately 196 weeks

  2. Part 1A and Part 1B: Duration of Response (DOR)

    DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

    Time frame: Up to approximately 196 weeks

  3. Part 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  4. Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

    Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  5. Part 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

    Time frame: Up to approximately 196 weeks

  6. Part 1A and Part 1B: Niraparib Concentrations

    Blood samples were obtained to analyze niraparib concentration levels.

    Time frame: 2.5 hours (HR) and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

  7. Part 1A and Part 1B: Dostarlimab Concentrations

    Blood samples were collected for PK analysis of Dostarlimab.

    Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12, 18, 24, 30, 36; End of Treatment (Up to approximately 196 weeks)

  8. Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

    Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to approximately 196 weeks

  9. Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

    The acceptability and palatability for participants who received niraparib tablet or TfOS were evaluated by using a questionnaire.

    Time frame: At Week 1 of Cycle 1

  10. Part 2 Safety-run in: Objective Response Rate (ORR)

    ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR, using RECIST v1.1 or INRC (neuroblastoma only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

    Time frame: Up to approximately 196 weeks

  11. Part 2 Safety-run in: Duration of Response (DOR)

    DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). It is calculated for participants with a BOR of confirmed CR or PR. If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

    Time frame: Up to approximately 196 weeks

  12. Part 2 Safety-run in: Disease Control Rate (DCR)

    DCR is the percentage of participants achieving a BOR of confirmed CR, PR, or stable disease (SD) by RECIST v1.1 or INRC (neuroblastoma only). Per RECIST v1.1: CR is disappearance of all target lesions and pathological lymph nodes \<10 mm in short axis; PR is ≥30% decrease in lesion diameters from baseline; SD is neither sufficient shrinkage for PR nor sufficient increase for PD. Per INRC: CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

    Time frame: Up to approximately 196 weeks

  13. Part 2 Safety-run in: Progression-free Survival (PFS)

    PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 or INRC (in participants with neuroblastoma only) based on Investigator assessment, or death from any cause (whichever occurs first). Per RECISTv1.1: PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Per INRC: PD is \>20% lesion size increase, new lesions, or increased marrow tumor infiltration (\>5%).

    Time frame: Up to approximately 196 weeks

  14. Part 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  15. Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

    Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  16. Part 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

    Time frame: Up to approximately 196 weeks

  17. Part 2 Safety-run in: Niraparib Concentrations

    Blood samples were obtained to analyze niraparib concentration levels.

    Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, Pre-dose on Cycle 1 Week 2 and Pre-dose and 5 HR post-dose on Cycle 2 Week 1

  18. Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1

    ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1. CR was defined as disappearance of all target and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

    Time frame: Up to approximately 196 weeks

  19. Part 2A: Duration of Response (DOR) by the Investigator Using RECIST v1.1

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by RECIST v1.1 , based on Investigator assessment, or death (whichever occurs first). CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.

    Time frame: Up to approximately 196 weeks

  20. Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1

    DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) by RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Up to approximately 196 weeks

  21. Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1

    PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 , based on Investigator assessment, or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

    Time frame: Up to approximately 196 weeks

  22. Part 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  23. Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

    Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  24. Part 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

    Time frame: Up to approximately 196 weeks

  25. Part 2A: Niraparib Concentrations

    Blood samples were obtained to analyze niraparib concentration levels.

    Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

  26. Part 2A: Dostarlimab Concentrations

    Blood samples were collected for PK analysis of Dostarlimab.

    Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4 and 6; End of Treatment (Up to approximately 196 weeks)

  27. Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

    Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to approximately 196 weeks

  28. Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

    The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

    Time frame: At Week 1 of Cycle 1

  29. Part 2B: Duration of Response (DOR) by the Investigator by INRC

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by INRC , based on Investigator assessment, or death (whichever occurs first). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%. PD is \>20% lesion size increase,new lesions or increased tumor infiltration in bone marrow.

    Time frame: Up to approximately 196 weeks

  30. Part 2B: Disease Control Rate (DCR) by the Investigator by INRC

    DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or SD by INRC. CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

    Time frame: Up to approximately 196 weeks

  31. Part 2B: Progression-free Survival (PFS) by the Investigator by INRC

    PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by INRC , based on Investigator assessment, or death (whichever occurs first). PD is \>20% lesion size increase, new lesions, or increased tumor infiltration in bone marrow.

    Time frame: Up to approximately 196 weeks

  32. Part 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  33. Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

    Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to approximately 196 weeks

  34. Part 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

    A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

    Time frame: Up to approximately 196 weeks

  35. Part 2B: Niraparib Concentrations

    Blood samples were obtained to analyze niraparib concentration levels.

    Time frame: 2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2

  36. Part 2B: Dostarlimab Concentrations

    Blood samples were collected for PK analysis of Dostarlimab.

    Time frame: Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12 and 18; End of Treatment (Up to approximately 196 weeks)

  37. Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

    Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

    Time frame: Up to approximately 196 weeks

  38. Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

    The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

    Time frame: At Week 1 of Cycle 1

07

Results

Posted Jan 21, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Started117531173
Dlt-evaluable population8622003
Intent-to-treat (itt) population11653003
Modified intent-to-treat (mitt) population0000980
Pharmacokinetic (pk) population117531173
Completed0000000
Not completed117531173
Withdrew: Death7333121
Withdrew: Lost to follow-up0000100
Withdrew: Physician decision0000500
Withdrew: Withdrawal by subject0000010
Withdrew: Study terminated by sponsor1000001
Withdrew: Reached protocol-defined stopping criteria3420441

Outcome measures

PrimaryPart 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)

DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Number of Participants With Dose-limiting Toxicities (DLT)1122
PrimaryPart 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)

DLT referred to adverse effects within the first 42 days of treatment, indicating the maximum tolerated dose. DLTs included treatment-related Grade (G) 4 non-haematologic AEs or G3 AEs unresolved to G≤1 within 48 hours. G3/4 non-haematologic lab abnormalities were DLTs if causing hospitalization or persisting ≥7 days with symptoms or requiring intervention. Haematologic DLTs included prolonged G4 thrombocytopenia, G3/4 thrombocytopenia with bleeding or transfusion needs, prolonged G4 neutropenia, G3/4 neutropenia with infection, and G3/4 anemia requiring transfusion. Other criteria included Cycle 2 delays \>2 weeks, unresolved G≥2 uveitis/endocrine toxicity, persistent colitis/diarrhea, unresolved G3/4 immune-related AEs, G≥3 infusion reactions, hemophagocytic lymphohistiocytosis, posterior reversible encephalopathy syndrome, and treatment-related G5 AE. DLT-evaluable participants completed ≥2 cycles with ≥80% of planned niraparib and ≥2 dostarlimab infusions or had a DLT.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)
ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Part 2 Safety-run in: Number of Participants With Dose-limiting Toxicities (DLT)1
PrimaryPart 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events

Thrombocytopenia events were defined as treatment-related toxicities of Grade 3 or Grade 4 thrombocytopenia occurring within the first 42 days of study treatment. AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events
ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight- Based Dose) + Dostarlima b 7.5 mg/kg
Part 2 Safety-run in: Number of Participants With Grade ≥3 Thrombocytopenia Adverse Events0
PrimaryPart 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

PFS6 is defined as the percentage of participants without progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death at 6 months from the date of the first dose of study treatment. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Time frame:
At Month 6
Reported as:
Number · Percentage of Participants
Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Percentage of ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Progression-Free Survival at 6 Months Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.10 (0.0 to 33.6)
PrimaryPart 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)

ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using International Neuroblastoma Response Criteria (INRC). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)
Percentage of ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Objective Response Rate (ORR) by the Investigator Using International Neuroblastoma Response Criteria (INRC)0 (0.0 to 36.9)
SecondaryPart 1A and Part 1B: Objective Response Rate (ORR)

ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR using RECIST v1.1 or INRC (for neuroblastoma participants only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 1A and Part 1B: Objective Response Rate (ORR)
Percentage of ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Objective Response Rate (ORR)9 (0.2 to 41.3)0 (0.0 to 45.9)0 (0.0 to 52.2)0 (0.0 to 70.8)
SecondaryPart 1A and Part 1B: Duration of Response (DOR)

DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

Time frame:
Up to approximately 196 weeks
Reported as:
Median · Months
Part 1A and Part 1B: Duration of Response (DOR)
MonthsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Duration of Response (DOR)37.29 (NA to NA)———
SecondaryPart 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
TEAEs11753
SAEs6222
SecondaryPart 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)2502
SecondaryPart 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
TEAEs leading to Death3100
Treatment Discontinuation3112
SecondaryPart 1A and Part 1B: Niraparib Concentrations

Blood samples were obtained to analyze niraparib concentration levels.

Time frame:
2.5 hours (HR) and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Reported as:
Mean · nanogram/ millilitre (ng/mL)
Part 1A and Part 1B: Niraparib Concentrations
nanogram/ millilitre (ng/mL)Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Cycle 1 Week 1, 2.5 HR post-dose120.045 ± 198.677444.300 ± 58.075383.480 ± 107.4614383.900 ± 413.0918
Cycle 1 Week 1, 7 HR post-dose347.889 ± 133.9846254.571 ± 141.7096640.200 ± 449.5850522.500 ± 369.8168
Cycle 1 Week 2, 168 HR post-dose419.255 ± 203.6362396.286 ± 276.8006812.000 ± 704.5534887.667 ± 628.3664
SecondaryPart 1A and Part 1B: Dostarlimab Concentrations

Blood samples were collected for PK analysis of Dostarlimab.

Time frame:
Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12, 18, 24, 30, 36; End of Treatment (Up to approximately 196 weeks)
Reported as:
Mean · milligram/ litre (mg/L)
Part 1A and Part 1B: Dostarlimab Concentrations
milligram/ litre (mg/L)Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Cycle 1 Week 1, Day 1 pre-dose0.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
Cycle 1 Week 1, 1 hr post-dose58.291 ± 10.7135124.743 ± 30.926769.720 ± 9.8228129.000 ± 2.6458
Cycle 1 Week 2, 168 hrs post-dose21.045 ± 4.527655.314 ± 10.156828.660 ± 14.166155.600 ± 8.2286
Cycle 2 Week 1, 504 hrs post-dose12.256 ± 2.151835.100 ± 11.109513.240 ± 5.041143.000 ± 7.4953
Cycle 4 Week 1, Pre-dose23.100 ± NA81.400 ± NA——
Cycle 6 Week 1, Pre-dose25.100 ± NA103.000 ± NA——
Cycle 12 Week 1, Pre-dose21.400 ± NA58.400 ± NA——
Cycle 18 Week 1, Pre-dose21.200 ± NA60.900 ± NA——
Cycle 24 Week 1, Pre-dose12.400 ± NA———
Cycle 30 Week 1, Pre-dose33.800 ± NA———
Cycle 36 Week 1, Pre-dose33.500 ± NA———
End of Treatment, End of Treatment16.543 ± 8.601658.700 ± 47.281116.507 ± 13.635846.800 ± 40.5879
SecondaryPart 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab0000
SecondaryPart 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

The acceptability and palatability for participants who received niraparib tablet or TfOS were evaluated by using a questionnaire.

Time frame:
At Week 1 of Cycle 1
Reported as:
Count of participants · Participants
Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
ParticipantsPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg
Part 1A and Part 1B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires11752
SecondaryPart 2 Safety-run in: Objective Response Rate (ORR)

ORR is the percentage of participants with a best overall response (BOR) of confirmed CR or PR, using RECIST v1.1 or INRC (neuroblastoma only) as determined by the Investigator. Per RECIST v1.1: CR is disappearance of all target lesions, with pathological lymph nodes \<10 mm in short axis. PR is ≥30% decrease in sum of diameters of target lesions, referencing baseline sum (percent change from baseline). Per INRC: CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2 Safety-run in: Objective Response Rate (ORR)
Percentage of ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Part 2 Safety-run in: Objective Response Rate (ORR)0 (NA to NA)
SecondaryPart 2 Safety-run in: Duration of Response (DOR)

DOR is the time from first documented response (CR or PR) to first PD by RECIST v1.1 or INRC (neuroblastoma only), based on Investigator assessment, or death (whichever occurs first). It is calculated for participants with a BOR of confirmed CR or PR. If no PD or death occurs post-response, participants are censored at their last tumor assessment date. Per RECIST v1.1, CR is disappearance of all target lesions; PR is ≥30% decrease in lesion diameters from baseline; PD is ≥20% increase in lesion sum from nadir plus ≥5 mm absolute increase. Per INRC, CR is resolution of detectable disease, including soft tissue, bone, and bone marrow, with residual lesions \<10 mm, no bone marrow infiltration, and normal MIBG/FDG uptake. PR is a ≥30% decrease in lesion size, ≥50% reduction in bone involvement (MIBG/FDG), no new lesions, and bone marrow infiltration ≤5%. PD is \>20% lesion size increase, new lesions, or increased infiltration in bone marrow.

Time frame:
Up to approximately 196 weeks

No measurements were reported for this outcome.

SecondaryPart 2 Safety-run in: Disease Control Rate (DCR)

DCR is the percentage of participants achieving a BOR of confirmed CR, PR, or stable disease (SD) by RECIST v1.1 or INRC (neuroblastoma only). Per RECIST v1.1: CR is disappearance of all target lesions and pathological lymph nodes \<10 mm in short axis; PR is ≥30% decrease in lesion diameters from baseline; SD is neither sufficient shrinkage for PR nor sufficient increase for PD. Per INRC: CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2 Safety-run in: Disease Control Rate (DCR)
Percentage of ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Part 2 Safety-run in: Disease Control Rate (DCR)0 (NA to NA)
SecondaryPart 2 Safety-run in: Progression-free Survival (PFS)

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 or INRC (in participants with neuroblastoma only) based on Investigator assessment, or death from any cause (whichever occurs first). Per RECISTv1.1: PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Per INRC: PD is \>20% lesion size increase, new lesions, or increased marrow tumor infiltration (\>5%).

Time frame:
Up to approximately 196 weeks
Reported as:
Median · Months
Part 2 Safety-run in: Progression-free Survival (PFS)
MonthsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Part 2 Safety-run in: Progression-free Survival (PFS)1.68 (1.35 to 2)
SecondaryPart 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2 Safety-run in: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
TEAEs3
SAEs2
SecondaryPart 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Part 2 Safety-run in: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)2
SecondaryPart 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2 Safety-run in: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
ParticipantsPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Leading to Death0
Treatment Discontinuation2
SecondaryPart 2 Safety-run in: Niraparib Concentrations

Blood samples were obtained to analyze niraparib concentration levels.

Time frame:
2.5 HR and 7 HR post-dose on Cycle 1 Week 1, Pre-dose on Cycle 1 Week 2 and Pre-dose and 5 HR post-dose on Cycle 2 Week 1
Reported as:
Mean · ng/mL
Part 2 Safety-run in: Niraparib Concentrations
ng/mLPart 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Cycle 1 Week 1, 2.5 HR post-dose109.000 ± 121.7060
Cycle 1 Week 1, 7 HR post-dose292.067 ± 225.1404
Cycle 1 Week 2, Pre-dose329.200 ± 272.7140
Cycle 2 Week 1, Pre-dose338.667 ± 253.1291
Cycle 2 Week 1, 5 HR post-dose834.667 ± 612.8428
SecondaryPart 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1

ORR is defined as the percentage of participants who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1. CR was defined as disappearance of all target and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.1
Percentage of ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Objective Response Rate (ORR) by the Investigator Using RECIST v1.10 (0.0 to 33.6)
SecondaryPart 2A: Duration of Response (DOR) by the Investigator Using RECIST v1.1

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by RECIST v1.1 , based on Investigator assessment, or death (whichever occurs first). CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). PD was defined as At least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.

Time frame:
Up to approximately 196 weeks

No measurements were reported for this outcome.

SecondaryPart 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1

DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) by RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.1
Percentage of ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Disease Control Rate (DCR) by the Investigator Using RECIST v1.10 (0.0 to 33.6)
SecondaryPart 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by RECIST v1.1 , based on Investigator assessment, or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start).

Time frame:
Up to approximately 196 weeks
Reported as:
Median · Months
Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.1
MonthsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Progression-free Survival (PFS) by the Investigator Using RECIST v1.11.2 (0.7 to 2.1)
SecondaryPart 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With of Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
TEAEs11
SAEs4
SecondaryPart 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)2
SecondaryPart 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Leading to Death0
Treatment Discontinuation2
SecondaryPart 2A: Niraparib Concentrations

Blood samples were obtained to analyze niraparib concentration levels.

Time frame:
2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Reported as:
Mean · ng/mL
Part 2A: Niraparib Concentrations
ng/mLPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Cycle 1 Week 1, 2.5 HR post-dose217.212 ± 236.5667
Cycle 1 Week 1, 7 HR post-dose241.482 ± 143.3515
Cycle 1 Week 2, 168 HR post-dose354.100 ± 153.7909
SecondaryPart 2A: Dostarlimab Concentrations

Blood samples were collected for PK analysis of Dostarlimab.

Time frame:
Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose) on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4 and 6; End of Treatment (Up to approximately 196 weeks)
Reported as:
Mean · mg/L
Part 2A: Dostarlimab Concentrations
mg/LPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Cycle 1 Week 1, Day 1 pre-dose0.000 ± 0.0000
Cycle 1 Week 1, 1 hr post-dose135.509 ± 45.2007
Cycle 1 Week 2, 168 hrs post-dose65.022 ± 8.6129
Cycle 2 Week 1, 504 hrs post-dose45.000 ± 27.4571
Cycle 4 Week 1, Pre-dose46.900 ± 23.0517
Cycle 6 Week 1, Pre-dose133.000 ± NA
End of Treatment, End of Treatment74.338 ± 52.2281
SecondaryPart 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab0
SecondaryPart 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

Time frame:
At Week 1 of Cycle 1
Reported as:
Count of participants · Participants
Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
ParticipantsPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)
Part 2A: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires11
SecondaryPart 2B: Duration of Response (DOR) by the Investigator by INRC

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documented PD by INRC , based on Investigator assessment, or death (whichever occurs first). CR is resolution of all detectable disease, including soft tissue, bone, and bone marrow, with residual lesion measurements \<10 mm and no tumor infiltration in the bone marrow or abnormal MIBG/FDG uptake. PR: Significant reduction in tumor burden, including a ≥30% decrease in primary or metastatic lesion size and ≥50% reduction in bone involvement (MIBG/FDG), with no new lesions and bone marrow infiltration ≤5%. PD is \>20% lesion size increase,new lesions or increased tumor infiltration in bone marrow.

Time frame:
Up to approximately 196 weeks

No measurements were reported for this outcome.

SecondaryPart 2B: Disease Control Rate (DCR) by the Investigator by INRC

DCR is defined as the percentage of participants who have achieved a BOR of confirmed CR, confirmed PR, or SD by INRC. CR is resolution of all detectable disease (soft tissue, bone, marrow) with residual lesion \<10 mm, no tumor infiltration in the bone marrow, and no abnormal MIBG or FDG/PET uptake. PR is ≥30% decrease in lesion size, ≥50% bone involvement reduction (MIBG/FDG uptake), no new lesions, and bone marrow infiltration ≤5%. SD was defined as neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site. Bone marrow infiltration remains \>5%.

Time frame:
Up to approximately 196 weeks
Reported as:
Number · Percentage of Participants
Part 2B: Disease Control Rate (DCR) by the Investigator by INRC
Percentage of ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Disease Control Rate (DCR) by the Investigator by INRC38 (8.5 to 75.5)
SecondaryPart 2B: Progression-free Survival (PFS) by the Investigator by INRC

PFS is defined as the time from the date of the first dose of study treatment to the first documented PD, as determined by INRC , based on Investigator assessment, or death (whichever occurs first). PD is \>20% lesion size increase, new lesions, or increased tumor infiltration in bone marrow.

Time frame:
Up to approximately 196 weeks
Reported as:
Median · Months
Part 2B: Progression-free Survival (PFS) by the Investigator by INRC
MonthsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Progression-free Survival (PFS) by the Investigator by INRC2.9 (0.5 to 10.2)
SecondaryPart 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
TEAEs7
SAEs4
SecondaryPart 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)

Dostarlimab-Related Immune-Mediated AEs were reported. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)
ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Number of Participants With Dostarlimab-Related Immune-Mediated Adverse Events (imAEs)4
SecondaryPart 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation

A TEAE is any event that emerged during treatment and was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With TEAEs Leading to Death and Treatment Discontinuation
ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Leading to Death0
Treatment Discontinuation3
SecondaryPart 2B: Niraparib Concentrations

Blood samples were obtained to analyze niraparib concentration levels.

Time frame:
2.5 HR and 7 HR post-dose on Cycle 1 Week 1, 168 HR post-dose on Cycle 1 Week 2
Reported as:
Mean · ng/mL
Part 2B: Niraparib Concentrations
ng/mLPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Cycle 1 Week 1, 2.5 HR post-dose275.600 ± 330.9424
Cycle 1 Week 1, 7 HR post-dose329.571 ± 182.8432
Cycle 1 Week 2, 168 HR post-dose700.143 ± 571.6900
SecondaryPart 2B: Dostarlimab Concentrations

Blood samples were collected for PK analysis of Dostarlimab.

Time frame:
Pre-dose on Day 1; 1 HR post-dose on Cycle 1 Week 1; 168 HR post-dose on Cycle 1 Week 2; 504 HR post-dose on Cycle 2 Week 1; Pre-dose on Week 1 of Cycles 4, 6, 12 and 18; End of Treatment (Up to approximately 196 weeks)
Reported as:
Mean · mg/L
Part 2B: Dostarlimab Concentrations
mg/LPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Cycle 1 Week 1, Day 1 pre-dose0.000 ± 0.0000
Cycle 1 Week 1, 1 hr post-dose186.000 ± 117.4748
Cycle 1 Week 2, 168 hrs post-dose61.943 ± 13.5405
Cycle 2 Week 1, 504 hrs post-dose39.925 ± 13.4205
Cycle 4 Week 1, Pre-dose88.500 ± 22.3900
Cycle 6 Week 1, Pre-dose173.667 ± 90.4231
Cycle 12 Week 1, Pre-dose179.500 ± 24.7487
Cycle 18 Week 1, Pre-dose121.000 ± NA
End of Treatment, End of Treatment93.580 ± 69.6794
SecondaryPart 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab

Blood samples were collected for the analysis of the presence of ADAs using electrochemiluminescence. All samples were tested in screening and confirmatory assay, and positive samples were further characterized for antibody titers.

Time frame:
Up to approximately 196 weeks
Reported as:
Count of participants · Participants
Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab
ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Number of Participants With Positive Anti-Drug Antibody (ADAs) to Dostarlimab0
SecondaryPart 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires

The acceptability and palatability for participants who received niraparib tablet were evaluated by using a questionnaire.

Time frame:
At Week 1 of Cycle 1
Reported as:
Count of participants · Participants
Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires
ParticipantsPart 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)
Part 2B: Number of Participants Answered Acceptability and Palatability of Niraparib Via Questionnaires7

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected upto approximately 196 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)7/11 (63.6%)6/11 (54.5%)11/11 (100%)
Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg3/7 (42.9%)2/7 (28.6%)7/7 (100%)
Part 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kg3/5 (60%)2/5 (40%)5/5 (100%)
Part 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kg3/3 (100%)2/3 (66.7%)3/3 (100%)
Part 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)2/11 (18.2%)4/11 (36.4%)11/11 (100%)
Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)2/7 (28.6%)4/7 (57.1%)7/7 (100%)
Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
Abdominal painGastrointestinal disorders0/110/70/51/30/111/70/3
Alanine aminotransferase increasedInvestigations0/110/70/50/30/111/71/3
HypotoniaNervous system disorders0/110/70/51/30/110/70/3
Immune-mediated encephalitisNervous system disorders0/111/70/50/30/110/71/3
LethargyNervous system disorders0/110/70/51/30/110/70/3
EpistaxisRespiratory, thoracic and mediastinal disorders0/110/70/51/30/111/70/3
PyrexiaGeneral disorders0/110/70/50/31/112/70/3
Cerebral haemorrhageNervous system disorders0/110/71/50/30/110/70/3
HypoxiaRespiratory, thoracic and mediastinal disorders0/110/71/50/30/110/70/3
AnaemiaBlood and lymphatic system disorders0/110/70/50/30/111/70/3
Most frequent other events
Showing 10 of 142
Most frequent other events
EventPart 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kg
AnaemiaBlood and lymphatic system disorders7/113/72/53/33/113/72/3
LeukopeniaBlood and lymphatic system disorders0/112/72/50/32/110/73/3
NeutropeniaBlood and lymphatic system disorders0/111/71/50/31/110/72/3
ThrombocytopeniaBlood and lymphatic system disorders2/110/72/51/31/113/72/3
Abdominal painGastrointestinal disorders2/112/70/52/31/112/70/3
PainGeneral disorders0/110/70/52/32/110/70/3
Alanine aminotransferase increasedInvestigations0/114/71/52/30/111/71/3
Aspartate aminotransferase increasedInvestigations0/113/71/52/31/113/71/3
Platelet count decreasedInvestigations2/111/71/52/31/112/70/3
PyrexiaGeneral disorders7/111/71/50/30/111/71/3

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kgTotal
Mean13.9 ± 2.8413.7 ± 3.9913.0 ± 3.816.0 ± 1.0014.3 ± 2.4510.1 ± 2.9714.7 ± 1.5312.9 ± 3.50
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kgTotal
Female153353222
Male1022064125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg)Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kgPart 1A Cohort 1B: Niraparib 200 mg + Dostarlimab 3 mg/kgPart 1B Cohort 1: Niraparib AAOLF (Age-based Dose) + Dostarlimab 7.5 mg/kgPart 2A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Osteosarcoma)Part 2B: Niraparib 100 mg + Dostarlimab 7.5 mg/kg (Neuroblastoma)Part 2: Safety- Run-In Niraparib TfOS (Weight-based Dose) + Dostarlimab 7.5 mg/kgTotal
American Indian or Alaska Native00000000
Asian00001203
Native Hawaiian or Other Pacific Islander00000000
Black or African American00001001
White1175395343
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

2 sites
  • GSK Investigational Site
    Birmingham, B4 6NH, United Kingdom
  • GSK Investigational Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Apr 2025, 54 months.

Results were first posted in Jan 2026, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 10, 2020
StartActual
Oct 6, 2020
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Results first posted
Jan 21, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04544995
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Oct 6, 2020
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Results posted
Jan 21, 2026
Last update
Jan 21, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Dostarlimab

Start the discussion